At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,060 enrolled
Drug / intervention
epoetin beta [NeoRecormon]drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmaco-epidemiological Observational Study of the Clinical Benefit of NeoRecormon® in Cancer Patients With Anemia, According to Early Response to Treatment
In Brief
An observational study evaluating epoetin beta [NeoRecormon] for Anemia, Neoplasms. Completed, enrolled 1,060 participants across 1 site.
Detailed Summary
This observational study will evaluate the clinical benefit of NeoRecormon (epoetin beta) in daily routine practice in cancer patients with anemia. Data will be collected from patients who are receiving chemotherapy for a solid tumor or hematological malignancy. Patients will be followed for 28 weeks.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Neoplasms
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedJul 2010
Primary CompletionDec 2010
TodayJul 2026
First PostedJul 23, 2010
Enrollment StartJan 1, 2010
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.9 years ago
Interventions
epoetin beta [NeoRecormon]drug
As prescribed by physician